99mTc-Tilmanocept: A Novel Molecular Agent for Lymphatic Mapping and Sentinel Lymph Node Localization.

Article Details

Citation
Copy to clipboard

Surasi DS, O'Malley J, Bhambhvani P

99mTc-Tilmanocept: A Novel Molecular Agent for Lymphatic Mapping and Sentinel Lymph Node Localization.

J Nucl Med Technol. 2015 Jun;43(2):87-91. doi: 10.2967/jnmt.115.155960. Epub 2015 May 8.

PubMed ID
25956693 [ View in PubMed
]
Abstract

Preoperative lymphatic mapping in conjunction with intraoperative gamma-probe detection is widely used for sentinel node localization in melanoma, breast cancer, and other malignancies. (99m)Tc-radiocolloids have been the standard radiotracers used for sentinel node mapping. (99m)Tc-tilmanocept is a receptor-binding molecular imaging agent approved by the U.S. Food and Drug Administration for lymphatic mapping and lymph node localization in breast cancer, melanoma, clinically node-negative squamous cell carcinoma of the oral cavity, and other solid tumors. It has several advantages over conventional radiocolloids, including rapid injection site clearance, high sentinel node extraction, and low distal node accumulation, which can lead to efficient resource use.

DrugBank Data that Cites this Article

Drugs